NASDAQ:ELOX Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis $12.05 +0.30 (+2.55%) As of 06/26/2026 03:57 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eloxx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$10.11▼$12.9150-Day Range$0.25▼$66.4352-Week Range$10.11▼$17.50Volume28,345 shsAverage Volume23,523 shsMarket Capitalization$8.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States. Read More Eloxx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreELOX MarketRank™: Eloxx Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Eloxx Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eloxx Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.78% of the float of Eloxx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEloxx Pharmaceuticals has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eloxx Pharmaceuticals has recently decreased by 52.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEloxx Pharmaceuticals does not currently pay a dividend.Dividend GrowthEloxx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.43 News SentimentEloxx Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Eloxx Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest4 people have searched for ELOX on MarketBeat in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders25.90% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.Read more about Eloxx Pharmaceuticals' insider trading history. Receive ELOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELOX Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com ELOX Stock Analysis - Frequently Asked Questions How have ELOX shares performed this year? Eloxx Pharmaceuticals' stock was trading at $0.0121 on January 22, 2026. Since then, ELOX shares have increased by 99,486.8% and is now trading at $12.05. When did Eloxx Pharmaceuticals' stock split? Eloxx Pharmaceuticals shares reverse split on Monday, June 1st 2026.A 1-11 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. When did Eloxx Pharmaceuticals IPO? Eloxx Pharmaceuticals (ELOX) raised $33 million in an initial public offering (IPO) on Tuesday, June 9th 2026. The company issued 2,975,000 shares at a price of $11.00 per share. When does Eloxx Pharmaceuticals' quiet period expire? Eloxx Pharmaceuticals's quiet period expires on Monday, July 20th. Eloxx Pharmaceuticals had issued 2,975,000 shares in its IPO on June 9th. The total size of the offering was $32,725,000 based on an initial share price of $11.00. During Eloxx Pharmaceuticals' quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Sub-IndustryN/A Current SymbolNASDAQ:ELOX CIK1035354 Webwww.eloxxpharma.com Phone781-577-5300Fax908-864-4440EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$6.36 million Price / Sales1.31 Cash FlowN/A Price / Cash FlowN/A Book Value($85.17) per share Price / Book-0.14Miscellaneous Outstanding Shares690,000Free Float510,000Market Cap$8.31 million OptionableN/A Beta-1,932.72 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ELOX) was last updated on 6/28/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron, Unocal, and Texaco each confirmed the same energy technology worked - no fuel costs, no carb...Behind the Markets | SponsoredSell Tesla, Buy the New King of FSD CarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, ...Chaikin Analytics | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
